Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Cardiovascular effects of the DPP-4 inhibitors

(2012) Tessey Jose et al.   Diabetes & Vascular Disease Research

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

(2012) L. Azoulay et al.   BMJ-British Medical Journal

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study

(2011) Benjamin M. Scirica et al.   AMERICAN HEART JOURNAL

Association Between Glycemic Control and Adverse Outcomes in People With Diabetes Mellitus and Chronic Kidney Disease

(2011) Sabin Shurraw   ARCHIVES OF INTERNAL MEDICINE

Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice

(2011) Masanori Abe et al.   CURRENT DRUG METABOLISM

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*

(2011) U. Graefe-Mody et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

(2011) Midori Ito et al.   ENDOCRINE JOURNAL

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

(2011) M. Nowicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Why Should We Avoid the Use of Rosiglitazone?

(2011) Nasser Mikhail   SOUTHERN MEDICAL JOURNAL

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Determinants of Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study

(2010) Timothy M. E. Davis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients

(2009) S. P.B. Ramirez et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes

(2009) T. Ninomiya et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

(2008) Nasser Mikhail   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease

(2007) C. A. Schneider et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY